A two-stage phase II trial design utilizing both primary and secondary endpoints.
Phase II trials in oncology drug development are usually conducted to perform the initial assessment of treatment activity. The common designs in this setting, for example, Simon 2-stage designs, are often developed based on testing whether a parameter of interest, usually a proportion (e.g. response rate), is less than a certain level or not. These designs usually consider only one parameter. However, sometimes we may encounter situations where we need to consider not a single parameter, but multiple parameters. This paper presents a two-stage design in which both primary and secondary endpoints are utilized in the decision rules. The family-wise Type 1 error rate and statistical power of the proposed design are investigated under a variety of situations by means of Monte-Carlo simulations.
Lin
Xun
X
Pfizer Global Research and Development, La Jolla Laboratories, 10555 Science Center Drive, San Diego, CA 92121, USA. Xun.Lin@Pfizer.com
Allred
Randy
R
Andrews
Glen
G
D017322:Clinical Trials, Phase II as Topic / Q000379:methods*; D023381:Endpoint Determination; D006801:Humans; D009010:Monte Carlo Method; D012107:Research Design